Meeting
2012 Genitourinary Cancers Symposium
Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access programme (NCT01254279).
Authors
Amit Bahl
Bristol Haematology and Oncology Centre, Bristol, United Kingdom
Amit Bahl , Susan Masson , Zafar Malik , Alison J Birtle , Santhanam Sundar , Robert J Jones , Nicholas David James , Malcolm David Mason , Satish Kumar , David Bottomley , Anna Lydon , Simon Chowdhury , James Wylie , Johann Sebastian De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01254279
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 44)
DOI
10.1200/jco.2012.30.5_suppl.44
Abstract #
44
Poster Bd #
C10
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).
First Author: Amit Bahl
Poster
2014 ASCO Annual Meeting
Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).
First Author: Fred Saad
Poster
2015 Genitourinary Cancers Symposium
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Alice Clement-Zhao
Poster
2014 Genitourinary Cancers Symposium
Phase I clinical study of cabazitaxel plus prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in a Japanese population.
First Author: Shunji Takahashi